Beta-Blockers Found Ineffective for Heart Attack Recovery

Findings from the Global REBOOT Clinical Trial

According to НВ — Техно: The international REBOOT clinical trial has determined that beta-blockers-commonly prescribed to patients with normal heart function following an uncomplicated heart attack-are not only useless but may also pose potential risks. These findings were presented at the European Society of Cardiology Congress in Madrid and published in the prestigious New England Journal of Medicine. Heart attacks remain a leading cause of death worldwide, making this study highly relevant for current treatment protocols.

Led by researchers Valentín Fuster and Borja Ibáñez, the REBOOT study analyzed data from 8,505 patients across 109 hospitals in Spain and Italy. All participants had normal heart function after an uncomplicated heart attack and were monitored for a period of four years. The results showed that the medications did not lead to a significant reduction in mortality rates, recurrent heart attacks, or hospitalizations.

Impact on Women and Side Effects

A secondary analysis published in the European Heart Journal revealed an increased risk of death for women. Female patients with an ejection fraction of 50% or higher faced a 2.7% higher mortality risk. The follow-up period for this gender-specific analysis was 3.7 years. These findings raise serious concerns about the safety and effectiveness of beta-blockers, which are currently prescribed to more than 80% of patients upon hospital discharge.

Additionally, patients taking these drugs experienced side effects including:

• chronic fatigue
• bradycardia
• sexual dysfunction

The conclusions of this study could significantly influence clinical practice and post-heart attack treatment, as they question the rationale for using beta-blockers in such cases.

These results may prompt the medical community to reconsider treatment approaches for patients after a heart attack, especially given the high percentage of individuals receiving these medications. At the same time, further research is needed to more thoroughly examine the potential risks and benefits of beta-blocker use in different patient groups. This would help establish safer and more effective treatment protocols aligned with current scientific evidence.